Table 1. Antitumor Activity With Pembrolizumab in All Patients.
| Best Overall Response | No. (%) [95% CI] (N = 121) |
|---|---|
| Objective response rate (CR+PR) | 12 (9.9) [5.2-16.7]a |
| Disease control rate (CR+PR+SD) | 37 (30.6) [22.5-39.6] |
| CR | 0 [0-3] |
| PR | 12 (9.9) [5.2-16.7] |
| SD | 25 (20.7) [13.8-29.0] |
| No assessmentb | 13 (10.7) [5.8-17.7] |
| Progressive disease | 71 (58.7) [49.4-67.6] |
| Time to response, median (range), mo | 4.1 (2.0-6.3) |
| Duration of follow-up, median (range), moc | 13.3 (6.6-18.3) |
| Duration of response, median (range), mo | Not reached (1.9-14.4) |
Abbreviations: CR, complete response; PR, partial response; SD, stable disease.
a
A total of 7 of 12 responses were ongoing at analysis.
b
No assessment includes patients who did not have a postbaseline tumor assessment as of the data cutoff date because the scans were missing or because the patient discontinued the study or died before the first postbaseline scan.
c
Median duration of follow-up in responders.